UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
|
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 15, 2024, Aveanna Healthcare Holdings Inc, a Delaware corporation (the “Company”), its wholly owned subsidiary, Aveanna Healthcare LLC, and Shannon Drake, the Company’s Chief Legal Officer and Secretary, entered into a Separation and Transition Agreement (the “Separation Agreement”), pursuant to which Mr. Drake’s employment with the Company and his tenure as Chief Legal Officer and Secretary will terminate on March 31, 2024 (the “Separation Date”).
Pursuant to the Separation Agreement, during the period prior to the Separation Date, Mr. Drake and the Company will work to transition Mr. Drake’s roles to other persons designated by the Company, and he will continue to receive his current compensation and benefits in accordance with the terms of his previously filed employment agreement with the Company, entered into on March 26, 2017, as amended on March 16, 2020 (as amended, the “Employment Agreement”). In consideration for Mr. Drake’s execution of the Separation Agreement and his non-revocation of a waiver and release of claims relating thereto, Mr. Drake will be entitled to the following benefits under the Separation Agreement: (i) payment of twelve months of base salary following the Separation Date, payable in equal installments in accordance with the Company’s regular payroll practices; (ii) a cash payment in the amount of $240,000, representing Mr. Drake’s annual bonus for 2023, payable in the Spring of 2024, (iii) a cash payment in the amount of $240,000, together with a lump-sum cash bonus equal to Mr. Drake’s pro rated bonus for his period of employment in 2024, the aggregate of which amounts will become payable in the Spring of 2025; and (iv) certain continued medical coverage for a period terminating on the earliest of the second anniversary of the Separation Date or Mr. Drake becoming eligible to participate in coverage under another employer’s medical plans.
Additionally, with respect to Mr. Drake’s outstanding equity awards: (i) all options that are vested as of the Separation Date will remain outstanding and exercisable until their original respective expiration dates; (ii) all options that are unvested as of the Separation Date will remain outstanding and eligible to vest following the Separation Date in accordance with their respective terms, and, to the extent such unvested options become vested, they will remain exercisable until their original respective expiration dates; (iii) 50% of Mr. Drake’s restricted stock units (“RSUs”) granted in calendar years 2021, 2022 and 2023 will continue to be eligible to vest in accordance with their respective terms, and all other remaining unvested RSUs will be forfeited for no consideration on the Separation Date; and (iv) all of Mr. Drake’s performance stock units granted in calendar years 2022 and 2023 will be forfeited on the Separation Date.
For the twelve-month period immediately following the Separation Date, Mr. Drake will be subject to restrictive covenants in favor of the Company related to non-competition, non-solicitation, non-disparagement and confidentially, in each case as set forth in the Employment Agreement.
The foregoing description of the Separation Agreement is only a summary and is qualified in its entirety by reference to the full text of such agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference in this Item 5.02.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
|
Description |
10.1 |
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Aveanna Healthcare Holdings Inc. |
Date: |
January 17, 2024 |
By: |
/s/ Jeff Shaner |
|
|
|
Jeff Shaner |
Exhibit 10.1
SEPARATION AND TRANSITION AGREEMENT
This Separation and Transition Agreement (this “Agreement”) is by and among Shannon Drake (the “Executive”), Aveanna Healthcare LLC (f/k/a BCPE Eagle Buyer LLC) (the “Subsidiary”) and Aveanna Healthcare Holdings Inc., a Delaware corporation (“Holdings,” and together with the Subsidiary, collectively, the “Company”). The Subsidiary, Holdings and the Executive are sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
WHEREAS, the Executive is currently employed as the Chief Legal Officer of the Company (the “CLO”) pursuant to that certain Employment Agreement, by and between the Executive and the Subsidiary, dated as of May 26, 2017, as amended pursuant to that certain Amendment to Employment Agreement, by and between the Executive and the Subsidiary dated March 16, 2020 (collectively, the “Employment Agreement”);
WHEREAS, capitalized terms used but not otherwise defined herein shall have the meaning ascribed thereto in the Employment Agreement;
WHEREAS, the Parties have agreed that Executive’s employment with the Company will terminate on March 31, 2024 (the “Separation Date’); and
WHEREAS, the Parties wish to document the terms and conditions of the Executive’s transition out of, and separation from, the Executive’s employment with the Company.
NOW, THEREFORE, for the promises and covenants set forth herein and for such other good and valuable consideration, the receipt of which is hereby acknowledged, the Executive, the Subsidiary and Holdings enter into this Agreement on the following terms and conditions:
1
DOCPROPERTY "CUS_DocIDChunk0" ACTIVE 692491197v1
2
DOCPROPERTY "CUS_DocIDChunk0" ACTIVE 692491197v1
3
DOCPROPERTY "CUS_DocIDChunk0" ACTIVE 692491197v1
4
DOCPROPERTY "CUS_DocIDChunk0" ACTIVE 692491197v1
[Signature Page Follows]
5
DOCPROPERTY "CUS_DocIDChunk0" ACTIVE 692491197v1
IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the date set forth below.
AVEANNA HEALTHCARE HOLDINGS INC.
By: /s/ Ed Reisz
Name: Ed Reisz
Title: Chief Administrative Officer
Dated: January 15, 2024
AVEANNA HEALTHCARE LLC
By:
Name:
Title:
Dated:
EXECUTIVE
/s/ Shannon Drake
Shannon Drake
Dated: January 15, 2024
6
DOCPROPERTY "CUS_DocIDChunk0" ACTIVE 692491197v1
EXHIBIT A
The chart below is subject to the terms of the Separation and Transition Agreement that this Exhibit A is appended (the “Agreement”).
Grant Year |
Equity Award |
Outstanding as of 3/31/2024 |
2017 |
Options (Time-Based) |
141,974 All vested as of 3/31/2024 |
2017 |
Options (Performance-Based) |
141,974 All unvested as of 3/31/2024 |
2020 |
Options (Time-Based) |
51,250 60% vested as of 3/31/24 (30,750) |
2020 |
Options (Performance-Based) |
51,250 All unvested as of 3/31/2024 |
2021 |
RSUs |
125,000 All unvested as of 3/31/24 Subject to the terms of Section 2(b) of the Agreement, one-half of the RSUs will continue to vest in accordance with their terms and all other remaining unvested RSUs will be forfeited for no consideration on the Separation Date |
2022 |
RSUs |
60,852 All unvested as of 3/31/24 Subject to the terms of Section 2(b) of the Agreement, one-half of the RSUs will continue to vest in accordance with their terms and all other remaining unvested RSUs will be forfeited for no consideration on the Separation Date |
DOCPROPERTY "CUS_DocIDChunk0" ACTIVE 692491197v1
Grant Year |
Equity Award |
Outstanding as of 3/31/2024 |
2022 |
PSUs |
60,852 All unvested as of 3/31/2024 Subject to the terms of Section 2(b) of the Agreement, all PSUs will be forfeited for no consideration on the Separation Date
|
2023 |
RSUs |
187,500 All unvested as of 3/31/24 Subject to the terms of Section 2(b) of the Agreement, one-half of the RSUs will continue to vest in accordance with their terms and all other remaining unvested RSUs will be forfeited for no consideration on the Separation Date |
2022 |
PSUs |
187,500 All unvested as of 3/31/2024 Subject to the terms of Section 2(b) of the Agreement, all PSUs will be forfeited for no consideration on the Separation Date
|
DOCPROPERTY "CUS_DocIDChunk0" ACTIVE 692491197v1
EXHIBIT B
RELEASE AGREEMENT
[attached hereto]
DOCPROPERTY "CUS_DocIDChunk0" ACTIVE 692491197v1
RELEASE AGREEMENT
This Release Agreement (this “Release Agreement”) is entered into by and among. Shannon Drake (“Executive”), Aveanna Healthcare LLC (f/k/a BCPE Eagle Buyer LLC) (the “Subsidiary”) and Aveanna Healthcare Holdings Inc., a Delaware corporation (“Holdings,” and, together with the Subsidiary, collectively, the “Company”). INTENDING TO BE LEGALLY BOUND, Executive, the Subsidiary and Holdings agree as follows.
DOCPROPERTY "CUS_DocIDChunk0" ACTIVE 692491197v1
DOCPROPERTY "CUS_DocIDChunk0" ACTIVE 692491197v1
DOCPROPERTY "CUS_DocIDChunk0" ACTIVE 692491197v1
[Signature Page Follows]
DOCPROPERTY "CUS_DocIDChunk0" ACTIVE 692491197v1
AVEANNA HEALTHCARE HOLDINGS INC.
By: /s/ Ed Reisz
Name: Ed Reisz
Title: Chief Administrative Officer Date: January 15, 2024
AVEANNA HEALTHCARE LLC
By:
Name:
Title: Date:
SHANNON DRAKE, as Executive
/s/ Shannon Drake
Date:
[Signature Page to the Release Agreement]
DOCPROPERTY "CUS_DocIDChunk0" ACTIVE 692491197v1
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end
Document And Entity Information |
Jan. 15, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jan. 15, 2024 |
Entity Registrant Name | Aveanna Healthcare Holdings Inc. |
Entity Central Index Key | 0001832332 |
Entity Emerging Growth Company | false |
Entity File Number | 001-40362 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 81-4717209 |
Entity Address, Address Line One | 400 Interstate North Parkway SE |
Entity Address, City or Town | Atlanta |
Entity Address, State or Province | GA |
Entity Address, Postal Zip Code | 30339 |
City Area Code | 770 |
Local Phone Number | 441-1580 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.01 per share |
Trading Symbol | AVAH |
Security Exchange Name | NASDAQ |
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end
<2U&6]3^?TER8
M&U27CF& H0735]XPZ$99] <
M11YNL4N_V>^].=U9(J<+IP.86?]O:W(^MA:P]"VJ4G[6:TG7DJP!4OY)OU?KO2?OC!&!RMN2Y,]PH<2?09L
M4'L> _A;+O@(279OPNB*.Z=Y6O'G=0$^$'X[$;@+1(,L,I@"-"M4E <&+C%;
MAXL2L,;048I&TWUK30'/:@R<8IH/!78 5I' X^,JF#*4LLX!TO9/(_TCD8L$
M%138/>@G28Z7LDZD$@H591QA+P/TK72J?Y)F ,J4'&-CW3$OT>84T%@X61X*
M)]/?0QG'^MK;&[\UU5O+(+N3MUH%;K,8.YD@9)O44HN _8+$ 6:'J&D6O>A%
MJDF7'9B